My research focuses on mechanisms of bypassing cell senescence with oncogenic-viruses or cellular telomerase related pathways, and these studies lead to discoveries of novel non-canonical functions of telomerase components (catalytic submit: hTERT protein, and template for telomere synthesis: TERC RNA) and a novel cell culture technology. This cell technology was licensed to a start-up biotechnology company, Propagenix (now acquired by StemCell Technologies) which is commercializing both the diagnostic as well as regenerative medicine applications. I have published more than 150 peer-reviewed articles in highly respected journals, including NEJM, Nature Protocols, PNAS, PLoS Pathogens, JVI, JBC, JMV, AJP. Currently, research areas in Liu laboratory (HPV and Cell Reprogramming Laboratory) include: 1. Applications of patient-derived cell models (both 2D and 3D) in cancer initiation and precision medicine, patient-derived or individualized tumor micro-environment and personalized cancer vaccines. 2. Bypassing cell senescence and translations: (A) HPV E6/E7, and targeting E6/E7 for therapeutics; (B) hTERT and non-canonical functions of telomerase, targeting hTERT protein and tumor microenvironment; (C) Targeting Myc pathways and tumor microenvironment epigenetically, and targeting E6/Myc interactions for treating HPV associated human cancer. (D) Biological mechanisms of cell aging and cancer initiation, especially roles of telomerase and telomeres in these processes. 3. Mechanisms of cell reprogramming: Roles of cytoskeleton, AIB1, BMI1, p53 and its variants in regulation of conditional reprogramming and cell senescence.